MSB

2.51%

97.0¢ mesoblast limited

So if the Americans think that we are about to lodge our first...

First 915 Last

Share
Profile

Follow
Bazsa

3,916 Posts.

1333

22/01/20

19:10

Post #: 42522579
Share

Originally posted by FullMoonFever: ↑

@ddwn

Article.

https://investmillion.com/mesoblast-limited-nasdaq-meso-surges-higher-after-presentation-at-the-2020-biotech-show-in-san-francisco/

Mesoblast Limited (NASDAQ: MESO) Surges Higher After At The 2020 Biotech Show In San Francisco
By
Invest Million Team
-
January 20, 2020
Mesoblast Limited (NASDAQ: MESO) was in the green on Friday, and closed the day with gains of 13%. This came after the company did a presentation for its commercial plans at the 2020 biotech show in San Francisco. In the presentation, the company announced that, the FDA had agreed to the choice of Ryoncil as the commercial name for its allogenic cell therapy treatment of AGVHD (Acute Graft Versus Host Disease).
While doing the presentation, the CEO Silviu Itescu stated that, the company was starting the year 2020 with excitement as they awaited approval by the FDA for Ryoncil as a treatment for AGVHD, a dangerous complication in bone marrow transplant. He further stated that, its revenues from royalties coming from sales in Japan of TEMCELL (A closely related product for treating AGVHD) gave insights on the potential of Ryoncil in the United States.
On top of that, the CEO stated that the company was working with its strategic partners for readouts on phase 3 trial of its lead product candidates in chronic low back pain and chronic heart failure, caused by degenerative disc disease.
In the presentation, the company also noted that in the course of the month, it will fill the first module of the rolling biologics license application for Ryoncil. It will then seek priority review by the FDA for BLA under the current fast track designation for its product candidate. It further announced that, if Ryoncil gets approved, it will be launched in the U.S market this year.
From a look at its price action, the stock surged higher in Friday’s session. It opened the day at $8.44 and traded between a low of $8.44 and a high of $10.39 before closing the day at $9.39. Volumes in the day stood at 402.74k.
About Mesoblast Limited
Mesoblast Limited is a Biopharma Company that focuses on the development of allogenic cellular medicines. The company is based in Melbourne, Australia

Expand

So if the Americans think that we are about to lodge our first moldul how will they react when they learn that the complete job has been done.

"it will fill the first module of the rolling biologics license application for Ryoncil."

MSB Price at posting: $2.91 Sentiment: Buy Disclosure: Held
12 Upvote

1 Great analysis

Reply

Top Stories

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

WGX

Westgold sets its sights on top five producer status through merger with Karora

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

GRX

GreenX picks up prospective copper project in Germany

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

There are more pages in this discussion • 16,943 more messages in this thread...

First 915 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 97.0¢		Change -0.025(2.51%)		Mkt cap ! $1.107B

Open	High	Low	Value	Volume
97.0¢	$1.01	96.5¢	$7.757M	7.884M

Buyers (Bids)

No.	Vol.	Price($)
10	274918	97.0¢

Sellers (Offers)

Price($)	Vol.	No.
97.5¢	974	1

View Market Depth

No.	Vol.	Price($)
6	103162	0.970
5	34741	0.965
11	125566	0.960
1	500	0.955
22	165429	0.950

Price($)	Vol.	No.
0.975	974	1
0.990	10204	1
1.000	14000	1
1.010	2877	1
1.015	60000	1

Last trade - 16.10pm 02/08/2024 (20 minute delay)

MSB (ASX) Chart

So if the Americans think that we are about to lodge our first...

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Westgold sets its sights on top five producer status through merger with Karora

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

GreenX picks up prospective copper project in Germany

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Venture to sniff out high-grade REE targets at Jupiter project, WA

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

So if the Americans think that we are about to lodge our first...

Top Stories

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Westgold sets its sights on top five producer status through merger with Karora

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

GreenX picks up prospective copper project in Germany

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Venture to sniff out high-grade REE targets at Jupiter project, WA

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News